First Merchants Corp boosted its holdings in Pfizer Inc. (NYSE:PFE) by 0.4% during the fourth quarter, HoldingsChannel.com reports. The fund owned 101,565 shares of the biopharmaceutical company’s stock after purchasing an additional 415 shares during the period. First Merchants Corp’s holdings in Pfizer were worth $4,434,000 as of its most recent filing with the Securities and Exchange Commission.

A number of other institutional investors and hedge funds have also bought and sold shares of PFE. Advocacy Wealth Management Services LLC raised its stake in Pfizer by 48.2% in the 4th quarter. Advocacy Wealth Management Services LLC now owns 793 shares of the biopharmaceutical company’s stock valued at $35,000 after acquiring an additional 258 shares during the period. Contravisory Investment Management Inc. increased its position in Pfizer by 182.6% during the 4th quarter. Contravisory Investment Management Inc. now owns 1,153 shares of the biopharmaceutical company’s stock worth $50,000 after buying an additional 745 shares during the period. Vestor Capital LLC bought a new position in Pfizer during the 3rd quarter worth $53,000. Arlington Partners LLC increased its position in Pfizer by 64.7% during the 4th quarter. Arlington Partners LLC now owns 2,141 shares of the biopharmaceutical company’s stock worth $93,000 after buying an additional 841 shares during the period. Finally, Ironwood Financial llc increased its position in Pfizer by 91.0% during the 4th quarter. Ironwood Financial llc now owns 2,229 shares of the biopharmaceutical company’s stock worth $97,000 after buying an additional 1,062 shares during the period. Institutional investors and hedge funds own 69.17% of the company’s stock.

Several research analysts have weighed in on PFE shares. Credit Suisse Group upgraded Pfizer from a “neutral” rating to an “outperform” rating in a research report on Thursday, January 31st. Zacks Investment Research cut Pfizer from a “hold” rating to a “sell” rating in a research report on Thursday, March 28th. Cantor Fitzgerald reiterated a “buy” rating and set a $53.00 price objective on shares of Pfizer in a research report on Tuesday, February 19th. Citigroup reiterated a “neutral” rating and set a $41.00 price objective on shares of Pfizer in a research report on Wednesday, February 20th. Finally, UBS Group cut Pfizer from a “buy” rating to a “neutral” rating in a research report on Wednesday, January 23rd. Fourteen research analysts have rated the stock with a hold rating and seven have given a buy rating to the stock. The company presently has an average rating of “Hold” and a consensus target price of $45.83.

In other news, insider Alexander R. Mackenzie sold 15,000 shares of the stock in a transaction on Monday, April 1st. The stock was sold at an average price of $42.83, for a total transaction of $642,450.00. Following the sale, the insider now directly owns 124,994 shares of the company’s stock, valued at approximately $5,353,493.02. The transaction was disclosed in a legal filing with the SEC, which is accessible through the SEC website. Also, major shareholder Pfizer Inc bought 50,000 shares of Pfizer stock in a transaction dated Monday, May 13th. The shares were bought at an average cost of $17.00 per share, for a total transaction of $850,000.00. The disclosure for this purchase can be found here. Over the last three months, insiders have sold 288,726 shares of company stock worth $12,534,617. 0.09% of the stock is currently owned by insiders.

PFE opened at $41.15 on Thursday. The firm has a market cap of $241.51 billion, a PE ratio of 13.72, a P/E/G ratio of 2.35 and a beta of 0.71. Pfizer Inc. has a 52-week low of $35.32 and a 52-week high of $46.47. The company has a current ratio of 1.54, a quick ratio of 1.27 and a debt-to-equity ratio of 0.60.

Pfizer (NYSE:PFE) last released its earnings results on Tuesday, April 30th. The biopharmaceutical company reported $0.85 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.75 by $0.10. The company had revenue of $13.12 billion for the quarter, compared to analyst estimates of $13.01 billion. Pfizer had a return on equity of 27.48% and a net margin of 21.31%. Pfizer’s quarterly revenue was up 1.6% on a year-over-year basis. During the same period in the prior year, the firm posted $0.77 EPS. Equities analysts forecast that Pfizer Inc. will post 2.89 earnings per share for the current year.

The business also recently announced a quarterly dividend, which will be paid on Friday, June 7th. Stockholders of record on Friday, May 10th will be issued a dividend of $0.36 per share. This represents a $1.44 annualized dividend and a dividend yield of 3.50%. The ex-dividend date of this dividend is Thursday, May 9th. Pfizer’s dividend payout ratio (DPR) is currently 48.00%.

ILLEGAL ACTIVITY WARNING: “Pfizer Inc. (PFE) Shares Bought by First Merchants Corp” was originally published by TheOlympiaReport and is the sole property of of TheOlympiaReport. If you are accessing this story on another publication, it was illegally stolen and reposted in violation of U.S. & international copyright and trademark legislation. The original version of this story can be viewed at https://theolympiareport.com/2019/05/16/pfizer-inc-pfe-shares-bought-by-first-merchants-corp.html.

About Pfizer

Pfizer Inc discovers, develops, manufactures, and sells healthcare products worldwide. It offers medicines and vaccines in various therapeutic areas, including internal medicine, vaccines, oncology, inflammation and immunology, and rare diseases under the Lyrica, Chantix/Champix, Eliquis, Ibrance, Sutent, Xalkori, Inlyta, Xtandi, Enbrel, Xeljanz, Eucrisa, BeneFix, Genotropin, and Refacto AF/Xyntha brands.

Recommended Story: The risks of owning bonds

Want to see what other hedge funds are holding PFE? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Pfizer Inc. (NYSE:PFE).

Institutional Ownership by Quarter for Pfizer (NYSE:PFE)

Receive News & Ratings for Pfizer Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Pfizer and related companies with MarketBeat.com's FREE daily email newsletter.